Speaker Profile
Ph.D., CEO, Kanso Diagnostics
Biography
Dr. Roy Rabinowitz, Ph.D. is dedicated to leading the future of rapid molecular testing, focused on developing platforms that enable end-to-end diagnostic solutions anywhere and anytime to improve the patient-doctor experience. He is a curiosity-driven scientist entrepreneur who converges molecular biology solutions with various disciplines to address unmet medical needs.Dr. Rabinowitz has a proven track record of creating biological solutions for real-world problems. He is the author of multiple scientific publications and a portfolio of patents covering diagnostic methods and tools, gene editing, and computational protein design methods. Dr. Rabinowitz is also a recipient of several distinguished awards for academic and professional excellence, including the Dan David Prize scholarship and the TEVA BioInnovation fellowship.
Talk
Molecular diagnostics, where and when it matters
Kansos "Molecular 2-Factor Authentication" platform delivers lab-grade diagnostics through isothermal amplification and unique labeling. By utilizing a microfluidics-free design, the system significantly reduces cost-per-test and simplifies manufacturing. Validated on patient samples, this plug-and-play solution enables rapid, affordable results at the point of care, beginning with womens health.
Clinical & Research Tools Showcase:
Kanso Diagnostics
Kanso is revolutionizing molecular diagnostics by making lab-grade testing affordable and immediate. Our breakthrough platform slashes cost-per-test, empowering providers to deliver high-accuracy results during a single patient visit. We are bridging the gap between clinical need and accessible, high-performance diagnostics.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Clinical & Research Tools Showcase will provide a 15-30 minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
